Skip to content
Wenlo
Sign in
← Markets

Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. (SUPN) — Form 8-K: Current report

8-KSUPNFiled Nov 2, 2026, 4:28 AM ET· Period Nov 2, 2026

About this filing

Supernus Pharmaceuticals, Inc. (SUPN) filed an 8-K on Nov 2, 2026 reporting entry into a material agreement (Item 1.01), a completed acquisition or sale of assets (Item 2.01), new debt or another financial obligation (Item 2.03) and 4 more items, with exhibits (Item 9.01).

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

  • Item 1.01 · Entry into a material agreement
  • Item 2.01 · Completed acquisition or sale of assets
  • Item 2.03 · New debt or another financial obligation
  • Item 3.03 · Change to shareholder rights
  • Item 5.01 · Change in control
  • Item 5.03 · Charter, bylaw or fiscal-year change
  • Item 7.01 · Regulation FD disclosure
  • Item 9.01 · Financial statements and exhibits

More SUPN filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.